Company intelligence / Profile preview

2seventy bio

Cambridge, Massachusetts, United States2seventybio.com ↗

Ownership: Public · TSVT
Employees: ~65
Development stage: Commercial

Overview

Abecma® (idecabtagene vicleucel), a BCMA-directed CAR-T cell therapy co-developed with Bristol Myers Squibb for relapsed/refractory multiple myeloma, has achieved commercial status. In early 2024 the company sold its remaining R&D pipeline to Regeneron to focus exclusively on maximizing the potential of Abecma. The company’s streamlined team now supports commercialization and access efforts for this product.

Therapeutic areas: Oncology
Modalities: Cell therapy (CAR-T)Gene therapy (historically; now focused on cell therapy)
Industry: Biotech

Drug pipeline

5 assets

CD33 CAR-T

4 more assets in the full pipeline.

Request access →

Partnerships

Bristol Myers Squibb (co-development/commercialization partner for Abecma)Regeneron (previously partnered on pipeline assets; acquired R&D portfolio in early/mid–2024)Novo Nordisk and JW Therapeutics were also mentioned as partners during earlier stages before strategic refocus.

Financials

Market cap: $266.1M
Total revenue: $22.9M
Enterprise value: $352.3M

Beyond the preview

Go deeper on 2seventy bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2seventy bio.

Explore the full profile